DSPE-Based Ligand-Cross-Linked Lipid Nanoparticles for BBB/BBTB Transport and Glioma Targeting
ACS Nano Medicine · 11.11.2026 · 1 (10) · 2703-2715
DOI: 10.1021/acsnanomed.6c00185 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano Medicine, online erschienen am 01.10.2026. Verfasst von Menghuan Tang und 11 weiteren Autor:innen. Die Arbeit nennt 51 Literaturangaben. Gefördert von: National Cancer Institute, National Institute of General Medical Sciences, National Institute of Biomedical Imaging and Bioengineering.
Abstract (Originalsprache)
Insufficient drug accumulation at intracranial tumor sites remains a major obstacle to effective glioma therapy, primarily due to restricted transport across the blood–brain barrier (BBB)/blood–brain tumor barrier (BBTB) and limited active targeting to glioma cells. Here, we report DSPE-based ligand-cross-linked lipid nanoparticles (DBLC LNPs) that integrate lipid-interface engineering, ligand cross-linking, and sequential glioma targeting within a single nanoparticle platform. In this design, maltobionic acid (MA)-functionalized DSPE was incorporated to promote glucose transporter 1 (GLUT1)-mediated BBB/BBTB transport, while 3-(propionamido)phenylboronic acid (PAPBA)-functionalized DSPE was introduced to recognize sialic acid-containing glycans on glioma cell surfaces. Compared with many complex multifunctional brain-tumor nanocarriers, this DSPE-based lipid-interface design introduces transport and recognition through defined lipid-ligand conjugates, thereby reducing synthetic complexity while maintaining formulation tunability and cargo-loading flexibility. Microfluidic technology further enabled controlled and reproducible preparation of DBLC LNPs, supporting their formulation compatibility and translational potential. In an orthotopic glioma model, vincristine (VCR)-loaded DBLC LNPs significantly suppressed glioma growth and prolonged survival. Magnetic resonance imaging (MRI)-based 3D reconstruction analysis of brain tumor further showed that DBLC LNPs@VCR inhibited tumor growth more effectively than free VCR, with tumor volume more than 6-fold lower than that in the free VCR group. Together, this study establishes a DSPE-based ligand-cross-linked LNP platform that combines sequential BBB/BBTB transport, drug-loading capacity, and formulation compatibility to improve therapeutic delivery for glioma treatments.
Förderung
- National Cancer Institute
- National Institute of General Medical Sciences
- National Institute of Biomedical Imaging and Bioengineering
- National Institute of Dental and Craniofacial Research
Zitieren
APA
Tang, M., Huang, Y., Zong, Q., Fan, R., Chowdhury, M. S. I., Au, N. T. H., Racacho, K. J., Aragon, A. S., Castaneda, F. J., Abdelkhaleq, A., Lin, T., & Li, Y. (2026). DSPE-Based Ligand-Cross-Linked Lipid Nanoparticles for BBB/BBTB Transport and Glioma Targeting. ACS Nano Medicine, 1(10), 2703-2715. https://doi.org/10.1021/acsnanomed.6c00185
Vancouver
Tang M, Huang Y, Zong Q, Fan R, Chowdhury MSI, Au NTH, et al. DSPE-Based Ligand-Cross-Linked Lipid Nanoparticles for BBB/BBTB Transport and Glioma Targeting. ACS Nano Medicine. 2026;1(10):2703-2715. doi:10.1021/acsnanomed.6c00185
BibTeX
@article{Tang2026,
author = {Tang, Menghuan and Huang, Yanyu and Zong, Qiufang and Fan, Ruohao and Chowdhury, Md Saiful I. and Au, Nhung Thi Hong and Racacho, Kelsey Jane and Aragon, Athena Sabaten and Castaneda, Francisco Javier and Abdelkhaleq, Adam and Lin, Tzu-Yin and Li, Yuanpei},
title = {DSPE-Based Ligand-Cross-Linked Lipid Nanoparticles for BBB/BBTB Transport and Glioma Targeting},
journal = {ACS Nano Medicine},
year = {2026},
volume = {1},
number = {10},
pages = {2703--2715},
doi = {10.1021/acsnanomed.6c00185}
}
EUVIMED